Prof. Mayra Ramos-Suzarte

Center of Molecular Immunology, Cuba

Professor

Email: [email protected]

Qualifications

2002 Ph.D., National Medical University, Cuba

1987 B.Sc., Havana University, Cuba

Publications (Selected)

1. Alfonso Alemán, S., Cáceres Lavernia, H., Camacho Sosa, K. and others. Real-World Effectiveness of Racotumomab as Maintenance Therapy in Advanced Non-Small Cell Lung Cancer Patients. Vaccines, 13(10), 1035, 2025.
2. Viada, C., Ramos M, L., García, F.A., Santiesteban, Y. and others. Machine Learning-Based Survival Prediction in Cancer Patients Treated with Nimotuzumab: A Real-World Data Mining Approach. Bionatura Journal, 2(2), 7, 2025.
3. Ruiz, R., Hernández, D., Viada, C., García, J. and Fors, M. Nimotuzumab and CIMAvax-EGF® in Advanced Cervical Cancer. Bionatura Journal, 1(10.70099/BJ/2024.01.04.20), 2024.
4. Ruiz, R., Hernández, D., Viada, C., García, J. and Fors, M. Tratamiento de tumores de ovario en progresión con la combinación terapéutica del AcM Nimotuzumab y la vacuna NGGM3/VSSP. Bionatura Journal, 2024.
5. Ramos, T.C., Suzarte, M.R., Hernández, D.S., Kourí, A.L., Rodríguez, R.P. and others. Use of monoclonal antibodies against the epidermal growth factor receptor in the treatment of patients with hypoxemic acute respiratory failure. US Patent App. 18/569,714, 2024.
6. Ramos-Suzarte, M., Gonzalez, C.V., Lopez, M.F. and Ramos, T.C. Efficacy of the therapeutic vaccine VAXIRA® in patients with advanced non-small cell lung cancer: Analysis of integrated clinical trial databases from 2006-2018. Clinical Trials and Case Studies, 3(6), 2024.
7. Piñol Jiménez, F.N., Capó de Paz, V.Á., Mederos Curbelo, O.N. and others. Ácidos biliares y esófago de Barrett. Revista Cubana de Cirugía, 63, 2024.
8. Camacho-Sosa, K., Ramos-Suzarte, M. and Viada-González, C.E. Índice neutrófilo-linfocito e índice plaquetas-linfocito: herramientas pronósticas del cáncer de pulmón. Revista Médica Electrónica, 45(6):1021-1029, 2023.
9. Camacho Sosa, K., Ramos Suzarte, M., Viada González, C.E. and others. Eficacia del nimotuzumab según índices inflamatorios en pacientes con cáncer de pulmón no microcítico avanzado. Revista Cubana de Medicina Militar, 52(3), 2023.
10. Díaz Londres, H., Jiménez Armada, J., Hernández Martínez, A. and others. Reposicionamiento del anticuerpo monoclonal humanizado cubano nimotuzumab en el tratamiento de pacientes con COVID-19. Anales de la Academia de Ciencias de Cuba, 13(2), 2023.
11. Nair, P., Casimiro, J.E.M., Mazumdarshaw, K., Bughani, U., Athalye, S.N. and others. Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19. US Patent App. 17/916,910, 2023.
12. de Lima, V.C.C., Corassa, M., Saldanha, E., Freitas, H., Arrieta, O., Raez, L. and others. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP). Lung Cancer, 170:114-121, 2022.
13. Londres, H.D., Armada, J.J., Martínez, A.H., Abdo Cuza, A.A., Sánchez, Y.H. and others. Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment. Immunotherapy, 14(7):521-530, 2022.
14. Abdo Cuza, A.A., Pi Avila, J., Machado Martinez, R., Jordan Gonzalez, J. and others. Nimotuzumab for COVID-19: case series. Immunotherapy, 14(3):185-193, 2022.
15. González Fernández, S., Amador García, Y., Boris Porras, L.G. and others. Nimotuzumab in the treatment of inoperable esophageal tumors of epithelial origin. Journal of Oncology, 2022(1), 4128946, 2022.
16. de-Castro-Suárez, N., Blanco-Santana, R., Cedeño-Arias, M. and others. Immunohistochemical assessment of epidermal growth factor receptor in autosomal dominant polycystic kidney disease: Study of two cases. Salud Quintana Roo, 8(31):7-11, 2022.
17. Mayra, R.S. Estudio observacional post Autorización de uso de Emergencia del itolizumab en el tratamiento de la COVID-19. Jornada 30 Aniversario CENCEC, 2021.
18. Crombet Ramos, T., Ramos Suzarte, M., Saavedra Hernández, D. and others. Reposicionamiento del anticuerpo monoclonal humanizado anti-CD6 itolizumab en el tratamiento de pacientes con COVID-19. Anales de la Academia de Ciencias de Cuba, 11(3), 2021.
19. González, C.E.V., Pérez, M.L., García, J.L.S., López, M.M.F., González, Y.S. and others. Meta-análisis de ensayos clínicos controlados de Nimotuzumab combinado con quimiorradioterapia en cáncer esofágico avanzado. Revista Cubana de Oncología, 19(3), 2021.
20. Arrieta, O., Turcott, J., Barrón, F., Ramos, M., Yendamuri, S., Barron, L.Z. and others. P48.09 body mass index predicts benefit from adding metformin to EGFR-TKIs in patients with lung adenocarcinoma: subanalysis from an RCT. Journal of Thoracic Oncology, 16(10):S1109-S1110, 2021.

Personal Details

WoS Researcher ID: IZE-2948-2023

https://scholar.google.com/citations?user=PzGSTv4AAAAJ&hl=es

https://www.researchgate.net/profile/Mayra-Ramos-Suzarte